References
- Lutsenko S. Human copper homeostasis: a network of interconnected pathways. Curr Opin Chem Biol 2010;14:211–217.
- de Romaña DL, Olivares M, Uauy R, Araya M. Risks and benefits of copper in light of new insights of copper homeostasis. J Trace Elem Med Biol 2011;25:3–13.
- Ford ES. Serum copper concentration and coronary heart disease among US adults. Am J Epidemiol 2000;151: 1182–1188.
- van den Berghe PV, Klomp LW. New developments in the regulation of intestinal copper absorption. Nutr Rev 2009;67:658–672.
- Zheng Y, Li XK, Wang Y, Cai L. The role of zinc, copper and iron in the pathogenesis of diabetes and diabetic complications: therapeutic effects by chelators. Hemoglobin 2008; 32:135–145.
- Cooper GJ. Selective divalent copper chelation for the treatment of diabetes mellitus. Curr Med Chem 2012;19: 2828–2860.
- Sidhu MS, Saour BM, Boden WE. A TACTful reappraisal of chelation therapy in cardiovascular disease. Nat Rev Cardiol 2013.
- Mazumder B, Mukhopadhyay CK, Prok A, Cathcart MK, Fox PL. Induction of ceruloplasmin synthesis by IFN-gamma in human monocytic cells. J Immunol 1997;159:1938–1944.
- Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Radic Biol Med 2000;28:1735–1744.
- Healy J, Tipton K. Ceruloplasmin and what it might do. J Neural Transm 2007;114:777–781.
- Gulec S, Collins JF. Investigation of iron metabolism in mice expressing a mutant Menke's copper transporting ATPase (Atp7a) protein with diminished activity (Brindled; Mo (Br) (/y)). PLoS One 2013;8:e66010.
- Yoshida K, Furihata K, Takeda S, Nakamura A, Yamamoto K, Morita H, et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995;9:267–272.
- Auclair S, Feillet-Coudray C, Coudray C, Schneider S, Muckenthaler MU, Mazur A. Mild copper deficiency alters gene expression of proteins involved in iron metabolism. Blood Cells Mol Dis 2006;36:15–20.
- Fosset C, McGaw BA, Abramovich D, McArdle HJ. Interrelations between ceruloplasmin and Fe status during human pregnancy. Biol Trace Elem Res 2004;98:1–12.
- Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002;22:439–458.
- Ranganathan PN, Lu Y, Jiang L, Kim C, Collins JF. Serum ceruloplasmin protein expression and activity increases in iron-deficient rats and is further enhanced by higher dietary copper intake. Blood 2011;118:3146–3153.
- Harris ZL. Aceruloplasminemia. J Neurol Sci 2003;207: 108–109.
- Kim CH, Park JY, Kim JY, Choi CS, Kim YI, Chung YE, et al. Elevated serum ceruloplasmin levels in subjects with metabolic syndrome: a population-based study. Metabolism 2002;51:838–842.
- Cunningham J, Leffell M, Mearkle P, Harmatz P. Elevated plasma ceruloplasmin in insulin-dependent diabetes mellitus: evidence for increased oxidative stress as a variable complication. Metabolism 1995;44:996–999.
- Reunanen A, Knekt P, Aaran RK. Serum ceruloplasmin level and the risk of myocardial infarction and stroke. Am J Epidemiol 1992;136:1082–1090.
- Daimon M, Susa S, Yamatani K, Manaka H, Hama K, Kimura M, et al. Hyperglycemia is a factor for an increase in serum ceruloplasmin in type 2 diabetes. Diabetes Care 1998; 21:1525–1528.
- Manttari M, Manninen V, Huttunen JK, Palosuo T, Ehnholm C, Heinonen OP, et al. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J 1994;15:1599–1603.
- Klipstein-Grobusch K, Grobbee DE, Koster JF, Lindemans J, Boeing H, Hofman A, et al. Serum caeruloplasmin as a coronary risk factor in the elderly: the Rotterdam Study. Br J Nutr 1999;81:139–144.
- Dadu RT, Dodge R, Nambi V, Virani SS, Hoogeveen RC, Smith NL, et al. Ceruloplasmin and heart failure in the atherosclerosis risk in communities study. Circ Heart Fail 2013; 6:936–943.
- Tang WH, Wu Y, Hartiala J, Fan Y, Stewart AF, Roberts R, et al. Clinical and genetic association of serum ceruloplasmin with cardiovascular risk. Arterioscler Thromb Vasc Biol 2012;32:516–522.
- Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, et al. Rationale and design of the LURIC study–a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001;2:S1–S73.
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33:S62–S69.
- Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51:5–40.
- Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–470.
- Wanner C, Frommherz K, Horl WH. Hyperlipoproteinemia in chronic renal failure: pathophysiological and therapeutic aspects. Cardiology 1991;78:202–217.
- Correale M, Totaro A, Abruzzese S, Di Biase M, Brunetti ND. Acute phase proteins in acute coronary syndrome: an up- to-date. Cardiovasc Hematol Agents Med Chem 2012;10: 352–361.
- Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor?Atherosclerosis 2006;187:238–250.
- Ferns GA, Lamb DJ, Taylor A. The possible role of copper ions in atherogenesis: the Blue Janus. Atherosclerosis 1997; 133:139–152.
- Meyer LA, Durley AP, Prohaska JR, Harris ZL. Copper transport and metabolism are normal in aceruloplasminemic mice. J Biol Chem 2001;276:36857–36861.
- Lutsenko S, Barnes NL, Bartee MY, Dmitriev OY. Function and regulation of human copper-transporting ATPases. Physiol Rev 2007;87:1011–1046.